| 80.45 -5.45 (-6.34%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 103.14 | 1-year : | 111.27 |
| Resists | First : | 88.3 | Second : | 95.26 |
| Pivot price | 85.94 |
|||
| Supports | First : | 77.05 | Second : | 64.1 |
| MAs | MA(5) : | 82.55  |
MA(20) : | 87.36 |
| MA(100) : | 90.95 |
MA(250) : | 60.96 |
|
| MACD | MACD : | -2.7 |
Signal : | -2.4 |
| %K %D | K(14,3) : | 38.2 |
D(3) : | 33.9 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 110.17 | Low : | 21.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SYRE ] has closed above bottom band by 16.9%. Bollinger Bands are 1.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 85.41 - 85.86 | 85.86 - 86.24 |
| Low: | 79.42 - 79.91 | 79.91 - 80.33 |
| Close: | 79.65 - 80.48 | 80.48 - 81.18 |
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Mon, 12 Oct 2026
UBS Initiates Spyre Therapeutics at Buy With $120 Price Target - Moomoo
Mon, 12 Oct 2026
UBS Initiates Spyre Therapeutics at Buy With $120 Price Target - Yahoo Finance
Fri, 09 Oct 2026
A 60-day lock-up at Spyre Therapeutics (SYRE) bars Fairmount sales without underwriters’ consent. - Stock Titan
Thu, 08 Oct 2026
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering - Yahoo Finance
Wed, 07 Oct 2026
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential - Seeking Alpha
Wed, 07 Oct 2026
Spyre Therapeutics Launches $350 Million Stock Offering Underwritten by Jefferies, TD, Leerink, Stifel - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 106.8 (%) |
| Shares Short | 12,840 (K) |
| Shares Short P.Month | 11,860 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.9 % |
| Return on Equity (ttm) | -23 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.31 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -41.91 |
| PEG Ratio | 0 |
| Price to Book value | 7.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -35.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|